Senti Bio Secures Additional Funding for Cancer Research
Senti Biosciences, Inc. (Nasdaq: SNTI), a pioneering clinical-stage biotechnology firm, has announced a significant boost in its journey towards innovative cancer therapies. The company has successfully received an additional $1.0 million grant from the California Institute for Regenerative Medicine (CIRM). This funding is part of an extensive $8 million grant awarded to propel the clinical development of its promising investigational therapy, SENTI-202.
Breakthrough in Chimeric Antigen Receptor Therapy
SENTI-202 represents a groundbreaking approach in cellular therapies, specifically designed as an off-the-shelf, Logic Gated chimeric antigen receptor natural killer (CAR-NK) cell therapy. This therapy targets hematologic malignancies, including acute myeloid leukemia (AML). The additional funding coincides with the achievement of crucial milestones in clinical study enrollment, highlighting Senti Bio's commitment to advancing cancer care.
Positive Progress in Clinical Trials
The ongoing Phase 1 clinical trial for SENTI-202 has yielded encouraging preliminary results, indicating the treatment's potential to significantly aid patients with relapsed or refractory conditions. Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Bio, voiced gratitude for CIRM's continued support, noting the company's dedication to pushing forward this critical research.
Encouraging Results and Patient Outcomes
Recent presentations at the American Association for Cancer Research (AACR) Annual Meeting showcased preliminary results indicating that SENTI-202 is well-tolerated among trial participants, with no dose-limiting toxicities reported. Notably, two out of three patients reaching the recommended Phase 2 dose showed a composite Complete Remission (cCR) outcome. These preliminary findings reinforce the therapy's capability to provide much-needed solutions in oncology.
Innovative Technology Behind SENTI-202
SENTI-202 is engineered to selectively target and eliminate cells expressing CD33 and/or FLT3, two markers associated with various hematologic cancers. By meticulously sparing healthy bone marrow cells, this innovative therapy seeks to reduce collateral damage often seen in traditional treatments.
Expanding the Reach of Gene Circuit Technology
At the heart of Senti Bio's advancements is its proprietary Gene Circuit platform. This technology enables the company to design therapies with enhanced precision, aiming to deliver targeted treatment that can spare healthy tissues while effectively combating cancer. Senti Bio's pipeline showcases cell therapies tackling various liquid and solid tumors, reflecting their commitment to innovation in challenging areas of oncology.
Commitment to Patient-Centric Solutions
Senti Bio continues to explore the breadth of its Gene Circuits across different modalities and indications beyond oncology. Their mission remains focused on developing therapies to provide new hope to patients burdened by incurable diseases. With a robust research agenda, Senti Bio exemplifies the drive to reshape cancer treatment.
Frequently Asked Questions
What is SENTI-202 and how does it work?
SENTI-202 is an investigational off-the-shelf CAR-NK cell therapy designed to attack and eliminate specific cancer cells while minimizing effects on healthy cells. It targets CD33 and FLT3 markers in hematologic malignancies.
How much funding has Senti Bio received from CIRM?
Senti Bio has received a total of $7.4 million from an $8 million grant awarded by CIRM to support its clinical development efforts.
What were the results of the Phase 1 clinical trial for SENTI-202?
The preliminary results showed that SENTI-202 was well tolerated, with significant patient responses including complete remission outcomes.
What technologies are used in Senti Bio's therapies?
Senti Bio employs innovative Gene Circuit technology to develop cell and gene therapies, providing them with enhanced control and specificity in targeting cancer cells.
Who can be contacted for more information about Senti Bio?
For investor inquiries, contact JTC Team, LLC, Jenene Thomas at (908) 824-0775 or via email at SNTI@jtcir.com.
